Back to top
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
DENTSPLY SIRONA Inc. (XRAY) - $25 value - yours FREE >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DENTSPLY SIRONA Inc. (XRAY) - $25 value - yours FREE >>
Image: Bigstock
DENTSPLY (XRAY) Scales a 52-Week High on Strong Q1 Results
Shares of DENTSPLY International Inc. (XRAY - Free Report) rallied to a new 52-week high of $64.59 on Jun 9 and closed a tad bit lower at $64.43. This represents a strong one-year return of approximately 22.1%, much better than the S&P 500’s return of -0.5% over the same period.
Currently, DENTSPLY has a Zacks Rank #3 (Hold). The stock has a market cap of $14.70 billion and a long-term expected earnings growth rate of 11.1%.
Growth Catalysts
DENTSPLY reported impressive first-quarter 2016 results. Adjusted earnings of 69 cents per share comfortably beat the Zacks Consensus Estimate by 6 cents. Earnings improved almost 17% on a year-over-year basis, primarily driven by strong top-line growth and margin expansion.
DENTSPLY SIRONA Price and Consensus
DENTSPLY SIRONA Price and Consensus | DENTSPLY SIRONA Quote
DENTSPLY provided a positive guidance. For full-year 2016, the company expects revenue growth of 4% to 6% at constant currency, driven by growth in both of its segments. Adjusted earnings are forecasted in the band of $2.70 to $2.80 per share.
We believe that the combined entity will benefit from revenue and cost synergies in 2016 and beyond. Also, the emerging markets provide significant opportunities for the company as these areas are vastly untapped with low dental products penetration.
However, integration will be a risk in the near term. Additionally, higher capital expenditure on product development coupled with persistent decline in sales is expected to put margins under pressure.
Estimate Revisions
However, the positives outweigh the negatives as evident from the recent estimate revisions. The Zacks Consensus Estimate for fiscal 2016 increased a penny to $2.75 over the last 30 days. Similarly, fiscal 2017 estimate increased by a penny to $3.10 over the same period.
Key Picks
Better-ranked stocks in the broad medical sector include Masimo Corp (MASI - Free Report) , IRadimed (IRMD - Free Report) and Exactech . While Masimo sports a Zacks Rank #1 (Strong Buy), IRadimed and Exactech have a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>